Pfizer’s tofacitinib succeeds in phase 3 ankylosing spondylitis trial
Pfizer said that a phase 3 clinical trial of XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS) has met its primary endpoint. The late-stage ... Read More
Pfizer said that a phase 3 clinical trial of XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS) has met its primary endpoint. The late-stage ... Read More